What the name refers to
An investigational dual glucagon and GLP-1 receptor agonist being studied in obesity and metabolic liver disease.
Evidence and regulatory context
Human clinical research exists, but this entry is not a broadly authorised consumer medicine. Trial results apply to the studied formulation, population and endpoints—not automatically to products sold online.
Reading product records
Keep evidence from an authorised or trial formulation separate from an online vial carrying the same name. Product records should identify the exact active ingredient and form, measured peptide amount, batch, storage history and whether the document covers identity, quantity or both.
Primary research links
Use current regulator and study records rather than treating a catalogue description as medical evidence.